Der var en 38% reduktion i risiko for udvikling af en SRE i forhold til placebo (relativ risiko 0, 62, p=0, 003).
There was also a 38% reduction in the risk of developing an SRE for Bondronat treated patients when compared with placebo (relative risk 0.62, p=0.003).